Resolvin E1 normalizes contractility, Ca2+ sensitivity and smooth muscle cell migration rate in TNF-α- and IL-6-pretreated human pulmonary arteries

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 309, Issue 8, 2015, Pages L776-L788

  Hiram, Roddy ^a   Rizcallah, Edmond ^a   Marouan, Sofia ^a   Sirois, Chantal ^a   Sirois, Marco ^a   Morin, Caroline ^a,b   Fortin, Samuel ^b   Rousseau, Eric ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b SCF Pharma   (Canada)

Author keywords

CPI 17; NF B; Overreactivity; Pulmonary hypertension; RVD1; RVE1

Indexed keywords

ANTIINFLAMMATORY AGENT; CALCIUM; CONTRACTILE PROTEIN; CONTRACTILE PROTEIN CPI 17; CONTRACTILE PROTEIN MYPT 1; GELATINASE B; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MONOACYLGLYCERIDE EICOSAPENTAENOIC ACID; PHORBOL DIBUTYRATE; POTASSIUM CHLORIDE; PROTEIN C FOS; PROTEIN C JUN; RESOLVIN E1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; 1-EICOSAPENTAENOYLGLYCEROL; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 5S,12R,18R-TRIHYDROXY-6Z,8E,10E,14Z,16E-EICOSAPENTAENOIC ACID; ACETYLSALICYLIC ACID; AUTACOID; DOCOSAHEXAENOIC ACID; IL6 PROTEIN, HUMAN; INDOLE DERIVATIVE; LIPOXYGENASE INHIBITOR; MMP9 PROTEIN, HUMAN; MONOACYLGLYCEROL; NONSTEROID ANTIINFLAMMATORY AGENT; RESOLVIN D1; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANTIINFLAMMATORY ACTIVITY; ARTERY CONSTRICTION; ARTICLE; BLOOD VESSEL REACTIVITY; CELL MIGRATION; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; GENE OVEREXPRESSION; HUMAN; HYPERSENSITIVITY; IN VITRO STUDY; INTRACELLULAR SIGNALING; PRECURSOR; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PULMONARY ARTERY; PULMONARY ARTERY MUSCLE; REGULATORY MECHANISM; SMOOTH MUSCLE FIBER; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; CELL MOTION; CYTOLOGY; DRUG EFFECTS; HYPERTENSION, PULMONARY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SMOOTH MUSCLE CELL; VASOCONSTRICTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CALCIUM; CELL MOVEMENT; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; HUMANS; HYPERTENSION, PULMONARY; IN VITRO TECHNIQUES; INDOLES; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LIPOXYGENASE INHIBITORS; MATRIX METALLOPROTEINASE 9; MODELS, BIOLOGICAL; MONOGLYCERIDES; MYOCYTES, SMOOTH MUSCLE; PULMONARY ARTERY; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASOCONSTRICTION;

EID: 84944448502     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00177.2015     Document Type: Article

References (49)

1. Ahmad M, Theofanidis P, Medford RM. Role of activating protein-1 in the regulation of the vascular cell adhesion molecule-1 gene expression by tumor necrosis factor- . J Biol Chem 20: 4616-4621, 1998.
2. Ameshima S, Golpon H, Cool CD, Chan D, Vandivier RW, Gardai SJ, Wick M, Nemenoff RA, Geraci MW, Voelkel NF. Peroxisome proliferator-activated receptor gamma (PPAR) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ Res 92: 1162-1169, 2003.
3. Ammit AJ, Lazaar AL, Irani C, O’Neill GM, Gordon ND, Amrani Y, Penn RB, Panettieri RA Jr. Tumor necrosis factor-alpha-induced secretion of RANTES and interleukin-6 from human airway smooth muscle cells: modulation by glucocorticoids and beta-agonists. Am J Respir Cell Mol Biol 26: 465-474, 2002.
4. Andrade PM. Effects of the fish-oil supplementation on the immune and inflammatory responses in elite swimmers. Prostaglandins Leukot Essent Fatty Acids 77: 139-145, 2007.
5. Arita ML, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, Yang R, Petasis NA, Serhan CN. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 201: 713-722, 2005.
6. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 109: 159-165, 2004.
7. Chu AJ, Walton MA, Prasad JK, Seto A. Blockade by polyunsaturated n-3 fatty acids of endotoxin-induced monocytic tissue factor activation is mediated by the depressed receptor expression in THP-1 cells. J Surg Res 87: 217-224, 1999.
8. Chu C. Lipids: COX-2’S new role in inflammation. Nat Chem Biol 6: 401-402, 2010.
9. Dave YA, McAuley DF, O’Kane CM. Matrix metalloproteinases in acute lung injury: mediators of injury and drivers of repair. Eur Respir J 38: 959-970, 2011.
10. Forrest AS, Joyce TC, Huebner ML, Ayon RJ, Wiwchar M, Joyce J, Freitas N, Davis AJ, Ye L, Duan DD, Singer CA, Valencik ML, Greenwood IA, Leblanc N. Increased TMEM16A-encoded calciumactivated chloride channel activity is associated with pulmonary hypertension. Am J Physiol Cell Physiol 303: C1229-C1243, 2012.
11. Fredman G, Serhan CN. Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution. Biochem J 437: 185-197, 2011.
12. Guibert C, Savineau JP, Crevel H, Marthan R, Rousseau E. Effect of short- term organoid culture on the pharmaco-mechanical properties of rat extra- and intrapulmonary arteries. Br J Pharmacol 146: 692-701, 2005.
13. Guilliams TG. Fatty acids: essential . . . Therapeutic. The Standard 2: 1-8, 2002.
14. Hiram R, Rizcallah E, Sirois C, Sirois M, Morin C, Fortin S, Rousseau E. Resolvin D1 reverses reactivity and Ca2 sensitivity induced by ET-1, TNF-α and IL-6 in the human pulmonary artery. Am J Physiol Heart Circ Physiol 307: H1547-H1558, 2014.
15. Hollborn M, Stathopoulos C, Steffen A, Wiedemann P, Kohen L, Bringmann A. Positive feedback regulation between MMP-9 and VEGF in human RPE cells. Invest Ophthalmol Vis Sci 48: 4360-4367, 2007.
16. Hosokawa S, Haraguchi G, Sasaki A, Arai H, Muto S, Itai A, Doi S, Mizutani S, Isobe M. Pathophysiological roles of nuclear factor B (NF- B) in pulmonary arterial hypertension: effects of synthetic selective NF- B inhibitor IMD-0354. Cardiovasc Res 99: 35-43, 2013.
17. Jiang C, Ting AT, Seed B. PPAR- agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82-86, 1998.
18. Jiang MJ, Morgan KG. Intracellular calcium levels in phorbol esterinduced contractions of vascular muscle. Am J Physiol Heart Circ Physiol 253: H1365-H1371, 1987.
19. Kazani S, Planaguma A, Ono E, Bonini M, Zahid M, Marigowda G, Wechsler ME, Levy BD, Israel E. Exhaled breath condensate eicosanoid levels associate with asthma and its severity. J Allergy Clin Immunol 132: 547-553, 2013.
20. Kobayashi T, Kim H, Liu X, Sugiura H, Kohyama T, Fang Q, Wen F, Abe S, Wang X, Atkinson JJ, Shipley JM, Senior RM, Rennard SI. Matrix metalloproteinase-9 activates TGF- and stimulates fibroblast contraction of collagen gels. Am J Physiol Lung Cell Mol Physiol 306: L1006-L1015, 2014.
21. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L. Expression and function of PPAR in rat and human vascular smooth muscle cells. Circulation 101: 1311-1318, 2000.
22. Leggett K, Maylor J, Undem C, Lai N, Lu W, Schweitzer K, King LS, Myers AC, Sylvester JT, Sidhaye V, Shimoda LA. Hypoxia-induced migration in pulmonary arterial smooth muscle cells requires calciumdependent upregulation of aquaporin 1. Am J Physiol Lung Cell Mol Physiol 303: L343-L353, 2012.
23. Lo CJ, Chiu KC, Fu M, Lo R, Helton S. Fish oil decreases macrophage tumor necrosis factor gene transcription by altering the NF- B activity. J Surg Res 82: 216-221, 1999.
24. Medzhito R. Origin and physiological roles of inflammation. Nature 454: 428-435, 2008.
25. Morin C, Fortin S, Rousseau E. Docosahexaenoic acid monoacylglyceride decrease endothelin-1 induced Ca2 sensitivity and proliferation in human pulmonary arteries. Am J Hypertens 25: 756-763, 2012.
26. Morin C, Guibert C, Sirois M, Vincent E, Gomes MM, Rousseau E. Effects of -hydroxylase product on distal human pulmonary arteries. Am J Physiol Heart Circ Physiol 294: H1435-H1443, 2008.
27. Morin C, Hiram R, Rousseau E, Blier PU, Fortin S. Docosapentaenoic acid monoacylglyceride reduces inflammation and vascular remodeling in experimental pulmonary hypertension. Am J Physiol Heart Circ Physiol 307: H574-H586, 2014.
28. Morin C, Sirois M, Echave V, Gomes MM, Rousseau E. EET displays anti- inflammatory effects in TNF-α stimulated human bronchi: putative role of CPI-17. Am J Respir Cell Mol Biol 38: 192-201, 2009.
29. Morin C, Sirois M, Echave V, Rizcallah E, Rousseau E. Relaxing effects of 17(18)-EpETE on arterial and airway smooth muscles in human lung. Am J Physiol Lung Cell Mol Physiol 296: L130-L139, 2009.
30. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 58: 2047-2046, 2011.
31. Oh DY, Talukdar S, Bae1 EJ, Imamura T, Morinaga H, Fan WQ, Li P, Lu WJ, Watkins SM, Olefsky JM. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142: 687-698, 2010.
32. Ortiz LA, Champion HC, Lasky JA, Gambelli F, Gozal E, Hoyle GW, Beasley MB, Hyman AL, Friedman M, Kadowitz PJ. Enalapril protects mice from pulmonary hypertension by inhibiting TNF-mediated activation of NF- B and AP-1. Am J Physiol Lung Cell Mol Physiol 282: L1209-L1221, 2002.
33. Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T, Lin BK, Gupta D, Shima Y, Chauhan D, Mitsiades C, Raje N, Richardson P, Anderson KC. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 98: 428-435, 2001.
34. Potus F, Graydon C, Provencher S, Bonnet S. Vascular remodeling process in pulmonary arterial hypertension, with focus on miR-204 and miR-126. Pulm Circ 4: 175-184, 2014.
35. Recchiuti A, Krishnamoorthy S, Fredman G, Chiang N, Serhan CN. MicroRNAs in resolution of acute inflammation: identification of novel resolvin D1-miRNA circuits. FASEB J 25: 544-560, 2011.
36. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 31: 986-1000, 2011.
37. Rodat-Despoix L, Aires V, Ducret T, Marthan R, Savineau JP, Rousseau E, Guibert C. Signalling pathways involved in the contractile response to 5-HT in human pulmonary artery. Eur Respir J 34: 1338-1347, 2009.
38. Rossi S, Di Filippo C, Ferraraccio F, Simonelli F, D’Amico M. Resolvin D1 reduces the immunoinflammatory response of the rat eye following uveitis. Mediators Inflamm 9: 318627, 2012.
39. Shimoda LA, Laurie SS. Vascular remodeling in pulmonary hypertension. J Mol Med 91: 297-309, 2013.
40. Simonneau G, Gatzoulis MA, Adatia I. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62 (Suppl 25): D34-D41, 2013.
41. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmac 56: 365-379, 2002.
42. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 104: 236-244, 2009.
43. Soon E, Holmes AM, Treacy CM, Doughty NJ, Southgate L, Machado RD, Trembath RC, Jennings S, Barker L, Nicklin P. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 122: 920-927, 2010.
44. Swanson D, Block R, Mousa SA. Omega-3 fatty acids EPA and DHA: health benefits throughout life. Adv Nutrit J 3: 1-7, 2012.
45. Tajsic T, Morrell NW. Smooth muscle cell hypertrophy, proliferation, migration and apoptosis in pulmonary hypertension. Compr Physiol 1: 295-317, 2011.
46. Uddin M, Levy B. Resolvins: Natural agonists for resolution of pulmonary inflammation. Progress Lipid 50: 75-88, 2011.
47. Vinolo MAR, Rodrigues HG, Nachbar RT, Curi R. Regulation of inflammation by short chain fatty acids. Nutrients 3: 858-876, 2011.
48. Xu ZZ, Zhang L, Liu T, Park JY, Berta T, Yang R, Serhan CN, Ji R. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central peripheral actions. Nat Med 16: 592-597, 2010.
49. Zhao Y, Joshi-Barve S, Barve S, Chen LH. Eicosapentaenoic acid prevents LPS induced TNF-α expression by preventing NF- B activation. J Am Coll Nutr 23: 71-78, 2004.